Processa Pharmaceuticals, Inc. (PCSA)
NASDAQ: PCSA · Real-Time Price · USD
2.980
-0.010 (-0.33%)
At close: Apr 24, 2026, 4:00 PM EDT
3.000
+0.020 (0.67%)
After-hours: Apr 24, 2026, 6:42 PM EDT
Processa Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2025
-
A de-risk approach focuses on improving existing cancer drugs, with a robust pipeline including PCS6422 and PCS11T showing strong efficacy and safety data. Strategic partnerships and regulatory expertise drive progress, with key catalysts expected in the second half of the year.
Fiscal Year 2024
-
A de-risked strategy focuses on improving existing chemotherapies by reducing toxicity and enhancing efficacy, with three oncology drugs in development and strong early clinical data. Interim phase II results for NGC-Capecitabine are expected in 2025, and the team is leveraging regulatory expertise for accelerated progress.